Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data UroGen Pharma Ltd. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
17.5
8.16
1.13
0.02
11.8
48
64.4
82.7
90.4
110
Cost of revenue
0.03
0.6
1.8
1.01
5.16
7.65
9.36
8.88
12.4
Gross profit
17.5
7.56
-0.68
0.02
10.8
42.9
56.7
73.4
81.5
97.3
Research and development
18.7
36.9
49.3
47.3
47.6
52.9
45.6
57.1
67.1
Selling, general and administrative
60.2
90.2
87.5
82.8
93.3
121
155
General and administrative
6.42
8.81
39.6
60.2
Operating expenses
27.5
76.5
109
Operating income
0.8
-20
-77.2
-109
-127
-92.3
-79
-65.5
-96.8
-125
Interest income
4.62
1.99
0.37
0.94
2.64
8.9
5.97
Other non-operating income
0.01
-0.12
-0.28
-0.15
0.07
0.84
-0.23
-0.67
Pre-tax income
-1.94
-20
-75.5
-105
-125
-109
-108
-98.3
-124
-153
Income tax
0.02
0.13
3.37
1.45
1.76
3.92
2.83
0.08
Net income
-1.94
-20
-75.7
-105
-128
-111
-110
-102
-127
-153
EBITDA
1
-19.8
-76.8
-109
-126
-91.5
-78.1
-64.7
-96.5
-125
EPS, basic
-1.91
-2.14
-4.80
-5.12
-5.90
-4.96
-4.81
-3.55
-2.96
-3.19
EPS, diluted
-1.91
-2.14
-4.80
-5.12
-5.90
-4.96
-4.81
-3.55
-2.96
-3.19
Shares, basic (weighted)
2.31
9.72
15.8
20.5
21.8
22.3
22.8
28.8
42.9
48.1
Shares, diluted (weighted)
2.31
9.72
15.8
20.5
21.8
22.3
22.8
28.8
42.9
48.1
Balance sheet
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
21.4
37
101
49.7
52.9
44.4
55.4
95
172
111
Short-term investments
36
97.4
49.2
44.8
44.6
56.2
111
49.3
Receivables
0.08
7.05
11.7
12.7
15.4
20.3
33.1
Inventory
0.11
0.32
1.96
4.83
4.33
5.67
9.23
16.5
Other current assets
0.4
0.96
0.67
1.03
3.36
7.48
11.1
10.3
8.85
14.7
Total current assets
22
74.5
102
149
116
114
129
169
276
186
Property, plant and equipment
0.74
0.81
0.95
0.98
2.05
1.97
1.3
0.69
0.66
0.64
Lease right-of-use assets
3.74
2.16
1.18
2.45
0
0.85
3.08
Long-term investments
48.6
1.89
0.68
0
4.5
5.02
0
Other non-current assets
0.25
0.24
0.32
0.26
0.07
1.31
2.74
2.04
0.59
5.16
Total assets
23.1
75.6
104
202
122
120
136
178
286
200
Accounts payable
1.88
2.84
4.27
4.69
3.27
5.79
5.53
6.51
10.9
12.1
Accrued liabilities
0.69
1.95
4.93
6.71
9.55
6.95
8.26
10.8
10.6
13.5
Deferred revenue
0.65
Total current liabilities
3.14
7.04
13.5
19.5
21.4
22.4
23.9
31.2
45.9
46.4
Long-term debt
0
97.5
98.6
122
122
Lease liabilities
2.6
1.5
0.4
1.59
0
0.06
2.65
Total liabilities
6.75
7.04
13.5
22.1
25.7
111
225
244
295
306
Total debt
0
97.5
98.6
122
125
Paid-in capital
43.5
116
213
408
453
476
488
614
797
854
Retained earnings
-27.2
-47.2
-123
-228
-357
-467
-577
-679
-806
-960
Other comprehensive income
0.28
0.27
-0.03
-0.11
0.01
0.06
0.02
Shareholders' equity
16.3
68.5
90.1
180
96.4
8.41
-89.4
-65.2
-8.8
-105
Total equity
16.3
68.5
90.1
180
96.4
8.41
-89.4
-65.2
-8.8
-105
Total liabilities and equity
23.1
75.6
104
202
122
120
136
178
286
200
Shares outstanding
2.31
13.8
16.2
21
22.2
22.5
23.1
32.5
42.2
48.4
Cash flow statement
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-1.94
-20
-75.7
-105
-128
-111
-110
-102
-127
-153
Depreciation and amortization
0.2
0.2
0.4
0.3
0.42
0.83
0.92
0.8
0.33
0.31
Stock-based compensation
1.97
6.3
30.6
30
28
23.1
10.6
9.34
13.1
12
Change in receivables
-0.08
0.08
-7.05
-4.67
-0.99
-2.74
-4.86
-12.8
Change in inventory
-0.11
-0.21
0.32
-1.96
-2.87
-0.36
-1.35
-3.55
-7.24
Change in payables
0.48
2.53
4.21
2.93
-1.25
2
0.28
4.16
10.9
0.29
Cash from operations
4.19
-9.57
-37.3
-71
-106
-84.9
-87.6
-76.4
-96.8
-162
Capital expenditures
-0.7
-0.27
-0.56
-0.33
-1.22
-0.75
-0.25
-0.19
-0.3
-0.29
Purchases of investments
-36
-198
-29.7
-51.9
-63
-49.8
-128
-77.4
Sales and maturities of investments
52.6
124
54.3
64.3
49.1
108
139
Cash from investing
-0.72
-36.3
35.3
-146
93.2
4.07
1.06
-0.95
-20.6
61.6
Debt issued
0
95.8
0
24.5
0
Stock issued
60.8
64.2
162
15.9
0
0
67.4
151
39.8
Cash from financing
-0.01
61.6
66.4
165
16.5
72.3
97.1
117
195
39.9
Net change in cash
3.46
15.7
64.4
-51.4
3.88
-8.5
10.6
39.6
77.2
-61
Free cash flow
3.49
-9.84
-37.9
-71.3
-107
-85.6
-87.8
-76.6
-97.1
-163
Income taxes paid
1.8
3
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $41.35 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
90.8%
Gross profit / revenue.
Operating margin
-35.3%
Operating income / revenue.
EBITDA margin
-35.1%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-52.0%
Pre-tax income / revenue.
Net margin
-51.7%
Net income / revenue.
FCF margin
-84.3%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-84.2%
Cash from operations / revenue.
Return on assets (ROA)
-38.7%
Net income / average total assets.
R&D / revenue
32.5%
Research and development expense / revenue.
SG&A / revenue
93.7%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
8.5%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
0.1%
Capital expenditures / revenue.
D&A / revenue
0.2%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
21.4%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
19.5%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
56.2%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
19.4%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
19.7%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
55.3%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-29.8%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
13.9%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
10.4%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
12.2%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
28.3%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
17.2%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
3.80x
Current assets / current liabilities.
Quick ratio
3.20x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
1.77x
(Cash + short-term investments) / current liabilities.
Debt / assets
79.2%
Total debt / total assets.
Liabilities / assets
152.4%
Total liabilities / total assets.
Net debt
$90.7M
Total debt - cash - short-term investments. Negative means more cash than debt.
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$1.94
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$3.75
Revenue / diluted weighted shares.
FCF per share
-$3.16
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$3.15
Cash from operations / diluted weighted shares.
Book value per share
-$2.71
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
10.7x
Market cap / revenue.
EV/Sales
11.2x
Enterprise value / revenue.
FCF yield
-7.9%
Free cash flow / market cap.
Earnings yield
-4.8%
Net income / market cap (the inverse of P/E).
What was UroGen Pharma Ltd.'s revenue in fiscal 2025?
UroGen Pharma Ltd. reported revenue of $109.8M for fiscal 2025, 21.4% higher than the year before.
Was UroGen Pharma Ltd. profitable in fiscal 2025?
No. It reported a net loss of $153.5M.
How much free cash flow did UroGen Pharma Ltd. generate in fiscal 2025?
Cash from operations of $162.4M minus capital expenditures of $289.0K left free cash flow of -$162.7M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.